Get the Stockscreener App
63.13
0.15%
0.095
Pre-market:
61.98
-1.15
-1.82%
Structure Therapeutics Inc Adr stock is traded at $63.13, with a volume of 624.12K.
It is up +0.15% in the last 24 hours and down -22.31% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$63.03
Open:
$63.23
24h Volume:
624.12K
Relative Volume:
0.44
Market Cap:
$4.46B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-28.44
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
-5.11%
1M Performance:
-22.31%
6M Performance:
+219.48%
1Y Performance:
+180.70%
1-Day Range:
$62.50
$64.99
1-Week Range:
$59.56
$66.25
52-Week Range:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
63.13 | 4.45B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million - AOL.com
GPCR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Handelsbanken Fonder AB Sells 212,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position - AOL.com
Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Structure Therapeutics price target on competitive positioning - Investing.com
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Monashee Investment Management LLC - MarketBeat
Did New Shelf Registration and Oral GLP-1 Progress Just Shift Structure Therapeutics' (GPCR) Investment Narrative? - Sahm
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating - Defense World
Structure Therapeutics shares could rise on obesity drug data, Cantor says - Investing.com
Structure Therapeutics (NASDAQ:GPCR) Price Target Cut to $113.00 by Analysts at Citizens Jmp - MarketBeat
Citizens cuts Structure Therapeutics stock price target on pipeline expansion - Investing.com
Structure Therapeutics (NASDAQ:GPCR) Releases Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Structure Therapeutics Inc. SEC 10-K Report - TradingView
Structure Therapeutics (NASDAQ: GPCR) turns Q4 profit as obesity pipeline advances - Stock Titan
Obesity pill aleniglipron trims 15% weight as maker turns quarterly profit - Stock Titan
Private Capital Advisors Inc. Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
How Structure Therapeutics Inc. (GPCR) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026 - TradingView
Structure Therapeutics Inc. (GPCR): Analyst Consensus Points To A 60% Upside Potential - DirectorsTalk Interviews
GPCRStructure Therapeutics Inc ADR Latest Stock News & Market Updates - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT) - The Globe and Mail
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake - AOL.com
Structure Therapeutics (GPCR) Gained from Favorable Clinical Data - Finviz
Aberdeen Group plc Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Structure Therapeutics (GPCR) Projected to Post Earnings on Thursday - MarketBeat
Structure Therapeutics surges on phase 2 data for GLP-1 pill aleniglipron - MSN
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST) - The Globe and Mail
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition? - TradingView
Readystate Asset Management LP Increases Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA) - The Globe and Mail
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Short Interest Down 17.8% in January - MarketBeat
(GPCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
FY2030 Earnings Forecast for GPCR Issued By HC Wainwright - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), CSL (CMXHF) - The Globe and Mail
Structure Therapeutics Inc. Sponsored ADR $GPCR Stake Lessened by Federated Hermes Inc. - MarketBeat
Assessing Structure Therapeutics (GPCR) Valuation As Oral Obesity Drug GSBR-1290 Advances In Phase 2 - Sahm
Principal Financial Group Inc. Decreases Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics’ Oral Obesity Drug Enters Phase 2 As Investor Focus Grows - Sahm
Structure Therapeutics (NASDAQ:GPCR) Shares Down 10.7%Here's Why - MarketBeat
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Pfizer (PFE) - The Globe and Mail
UPDATE 3-Novo Nordisk warns on profits and sales amid Trump drug price crackdown - Sahm
Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Praxis Precision Medicines (PRAX) - The Globe and Mail
Responsive Playbooks and the GPCR Inflection - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Cut to "Sell" at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Viking Therapeutics (VKTX) - The Globe and Mail
CCG Wealth Management LLC Sells 140,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Head to Head Review: Structure Therapeutics (NASDAQ:GPCR) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Genentech Licensing Deal and Guggenheim Reaffirmation Could Be A Game Changer For Structure Therapeutics (GPCR) - Sahm
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):